Global, regional, and national burden and trends of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in adolescents and adults aged 15-49 years from 2010 to 2021: insights from the global burden of disease study 2021.

Publication date: Jul 28, 2025

Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among those aged 15-49 years pose a severe public health challenge, yet our understanding of the burden of these diseases in this age group remains limited. This study aimed to evaluate the trends in MDR-TB and XDR-TB burden among this population from 2010 to 2021 across global, regional, and national levels. This study extracted four key indicators-incidence, prevalence, deaths, and disability-adjusted life years (DALYs) per 100,000 population-for MDR-TB and XDR-TB among 15-49 years from the 2021 Global Burden of Disease (GBD) study. It assessed the burden trends using percentage change (PC) and estimated annual percentage change (EAPC), with further analysis by age, sex, and sociodemographic index (SDI). In 2021, the global incidence, prevalence, deaths, and DALYs of MDR-TB among adolescents and young adults were 241,399, 336,746, 33,285, and 1,896,002, respectively. Global MDR-TB incidence and DALYs rates showed slight decreases since 2010, with EAPCs of -0. 76 and -2. 61, respectively. In 2021, the global incidence, prevalence, deaths, and DALYs of XDR-TB among adolescents and young adults were 12,861, 14,039, 2442, and 133,610, respectively. Since 2010, global XDR-TB incidence rates have increased, with an EAPC of 0. 57, while prevalence and death rates have decreased, with EAPCs of - 2. 67 and - 2. 87, respectively. The incidence and prevalence rates of MDR-TB were significantly decreased since 2010 in high SDI, high-middle SDI, and low SDI regions. The prevalence rate of XDR-TB was significantly decreased since 2010 in the high SDI and high-middle SDI regions, while a significant increase was observed in the middle SDI, low-middle SDI, and low SDI regions. Furthermore, a gradual decline was observed in the burden of MDR-TB and XDR-TB as the SDI level increases. The burden of MDR-TB and XDR-TB showed an upward trend during the COVID-19 epidemic. The burden of MDR-TB and XDR-TB among adolescents and young adults remained very severe, particularly in the middle SDI and low-middle SDI regions. The COVID-19 pandemic may impact the global burden of these drug-resistant tuberculosis. Targeted interventions are crucial to address this issue.

Open Access PDF

Concepts Keywords
Adolescents DALYs
Tuberculosis Disease burden
GBD 2021
MDR-TB
SDI
XDR-TB

Semantics

Type Source Name
disease MESH multidrug-resistant tuberculosis
disease MESH extensively drug-resistant tuberculosis
disease MESH death
disease MESH COVID-19
pathway REACTOME Reproduction
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Coenzyme M
drug DRUGBANK Trestolone
drug DRUGBANK Spinosad
disease MESH treatment failure
disease MESH relapse
disease MESH genitourinary cancers
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin
disease MESH cause of death
disease MESH educational attainment
disease IDO country
disease MESH uncertainty
disease IDO process
drug DRUGBANK Polyethylene glycol
disease MESH alcohol abuse
disease MESH infection
disease MESH malnutrition
pathway REACTOME Immune System
disease IDO susceptibility
disease IDO quality
drug DRUGBANK Bedaquiline
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Troleandomycin
disease MESH cancers
disease MESH infertility
disease MESH morbidity
disease MESH co infection
disease MESH silicotuberculosis
drug DRUGBANK Tretamine
drug DRUGBANK Testosterone

Original Article

(Visited 3 times, 1 visits today)